Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
AssigneeAstraZeneca AB
InventorsNicolas FLOCH, Matthew Joseph MARTIN, Paul David SMITH, Ursula GRAZINI
Life of this patent
Estimating the term…
Abstract
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with an AKT inhibitor.
Claims24
An EGFR TKI for use in the treatment of cancer in a human patient, wherein the EGFR TKI is administered in combination with an AKT inhibitor.
An EGFR TKI for use as claimed in any of the previous claims, wherein the AKT inhibitor is selected from the group consisting of miransertib (ARQ-092) or a pharmaceutically acceptable salt thereof, BAY1125976 or a pharmaceutically acceptable salt thereof, borussertib or a pharmaceutically acceptable salt thereof, AT7867 or a pharmaceutically acceptable salt thereof, CCT128930 or a pharmaceutically acceptable salt thereof, A-674563 or a pharmaceutically acceptable salt thereof, PHT-427 or a pharmaceutically acceptable salt thereof, Akti-1/2 or a pharmaceutically acceptable salt thereof, AT13148 or a pharmaceutically acceptable salt thereof, SC79 or a pharmaceutically acceptable salt thereof, capivasertib or a pharmaceutically acceptable salt thereof, miltefosine or a pharmaceutically acceptable salt thereof, perifosine or a pharmaceutically acceptable salt thereof, MK-2206 or a pharmaceutically acceptable salt thereof, RX-0201 or a pharmaceutically acceptable salt thereof, erucylphosphocholine or a pharmaceutically acceptable salt thereof, PBI-05204 or a pharmaceutically acceptable salt thereof, GSK690693 or a pharmaceutically acceptable salt thereof, afuresertib (GSK2110183) or a pharmaceutically acceptable salt thereof, uprosertib (GSK2141795) or a pharmaceutically acceptable salt thereof, XL-418 or a pharmaceutically acceptable salt thereof and ipatasertib (GDC-0068) or a pharmaceutically acceptable salt thereof.
An EGFR TKI for use as claimed in any of the previous claims, wherein the cancer is non-small cell lung cancer.
An EGFR TKI for use as claimed in any of the previous claims, wherein the cancer comprises a PIK3CA mutation.
An EGFR TKI for use as claimed in any of the previous claims, wherein the cancer is PTEN deficient.
The use of an EGFR TKI in the manufacture of a medicament for the treatment of cancer in a human patient, wherein the EGFR TKI is administered in combination with an AKT inhibitor.
A method of treating cancer in a human patient in need of such a treatment, comprising administering to the human patient a therapeutically effective amount of an EGFR TKI, wherein the EGFR TKI is administered in combination with a therapeutically effective amount of an AKT inhibitor.
A method of treating cancer in a human patient in need of such a treatment, comprising administering to the human patient a first amount of an EGFR TKI, and a second amount of an AKT inhibitor, where the first amount and the second amount together comprise a therapeutically effective amount.
A pharmaceutical composition comprising an EGFR TKI, an AKT inhibitor and a pharmaceutically acceptable excipient.
An AKT inhibitor for use in the treatment of cancer in a human patient, wherein the AKT inhibitor is administered in combination with an EGFR TKI.
Dependencies are inferred from the claim text.